[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"testicular-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:testicular-cancer":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,33,0,25,[9,53,106,175,206,238,260,292,317,357,388,418,447,469,496,521,545,572,639,662,684,707,727,747,774],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100054003","minimally-invasive-icg-guided-retroperitoneal-sentinel-lymph-node-dissection-in-the-primary-staging-of-testicular-cancer-versus-standard-of-care-100054003",false,"NCT07699640","Minimally-invasive ICG-guided Retroperitoneal Sentinel Lymph Node Dissection in the Primary Staging of Testicular Cancer Versus Standard of Care","RAISN 2: Prospective Randomized Trial of Minimally-invasive ICG-guided Retroperitoneal Sentinel Lymph Node Dissection in the Primary Staging of Testicular Cancer Versus Standard of Care","RAISN 2","Inclusion Criteria:\n\n* Male participants aged 18 years or older.\n* Clinically suspected testicular germ cell tumor based on physical examination and scrotal ultrasonography, with or without elevated serum tumor markers (AFP and\u002For β-hCG).\n* No radiological evidence of metastatic disease on preoperative contrast-enhanced computed tomography (CT) of the chest and abdomen (clinical stage I).\n* Eligible for radical inguinal orchiectomy.\n* Able to understand the study procedures and provide written informed consent.\n* Willing and able to comply with the study protocol and follow-up schedule.\n\nExclusion Criteria:\n\n* Previous scrotal or retroperitoneal surgery unrelated to germ cell tumor treatment, except surgery for cryptorchidism during childhood.\n* Previous malignancy requiring abdominal surgery, chemotherapy, or radiotherapy that could interfere with study participation.\n\nPrevious radiotherapy involving the retroperitoneum.\n\n* Known hypersensitivity to indocyanine green (ICG), iodine, or sodium iodide.\n* Severe medical condition that precludes surgery or study participation.\n* Psychiatric disorder or other condition preventing compliance with study procedures.\n* Inability to understand the German language sufficiently to provide informed consent and complete study assessments.\n* Individuals under legal guardianship or otherwise unable to provide legally valid informed consent.","MALE","18 Years",{"count":21,"type":22},171,"ESTIMATED","INTERVENTIONAL",[25],"NA","Testicular cancer is highly curable, but approximately 20-30% of patients with clinical stage I disease harbor occult retroperitoneal lymph node metastases that are not detected by conventional imaging. Current risk-adapted management may lead to overtreatment in some patients while failing to identify others who are at increased risk of relapse.\n\nThe RAISN 2 study evaluates whether minimally invasive indocyanine green (ICG)-guided retroperitoneal sentinel lymph node dissection can improve primary staging and risk stratification in patients with clinical stage I testicular cancer. Participants will be randomized in a 5:1 ratio to undergo either orchiectomy combined with ICG-guided sentinel lymph node dissection or standard orchiectomy followed by guideline-based surveillance.\n\nAll participants will undergo structured follow-up according to current clinical guidelines. The primary objective is to estimate the 2-year relapse-free survival of patients undergoing the sentinel lymph node approach. Secondary objectives include assessment of overall survival, relapse patterns, perioperative morbidity, quality of life, psychological outcomes, and the feasibility and safety of the procedure.\n\nThis multicenter study aims to determine whether sentinel lymph node-guided staging provides more accurate risk stratification while avoiding unnecessary treatment and maintaining oncological safety.",[28,29],"Testicular Cancer","Testicular Germ Cell Tumor",[28,29,31,32,33,34,35,36,37,38,39],"Stage I Testicular Cancer","Sentinel Lymph Node Biopsy","Sentinel Lymph Node Mapping","Indocyanine Green","ICG","Retroperitoneal Lymph Nodes","Minimally Invasive Surgery","Robot-Assisted Surgery","Active Surveillance","NOT_YET_RECRUITING","2026-07-08",{"date":43,"type":44},"2026-07-13","ACTUAL",{"date":46,"type":22},"2027-01",{"date":48,"type":22},"2031-01",{"name":50,"class":51},"Heinrich-Heine University, Duesseldorf","OTHER",10,{"id":54,"slug":55,"hasResults":12,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":12,"sex":61,"minAge":19,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":105},"100602476","destiny-pantumour04-100602476","NCT07124000","DESTINY-PANTUMOUR04","Effectiveness of T-DXd Across HER2-positive Solid Tumors in Patients Who Have Received Prior Systemic Treatment and Have no Satisfactory Alternative Treatment Options: A Hybrid Observational Study","DP-04","Inclusion Criteria:\n\n1. Adults aged ≥18 years\n2. Patients with locally advanced, unresectable, or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options as determined by the Investigator (see Exclusion Criterion 1 for excluded solid tumors);\n3. A clinician decision has been made for treatment with T-DXd in accordance with the FDA label;\n4. HER2-positive (IHC 3+) by local testing prior to study enrolment at the time of signed and dated informed consent;\n5. Patients who are willing and able to provide a signed and dated informed consent.\n\nExclusion Criteria:\n\n1. Primary diagnosis of adenocarcinoma of the breast, adenocarcinoma of the colon or rectum, NSCLC, adenocarcinoma of the gastric body or gastroesophageal junction or hematological malignancies;\n2. Prior T-DXd therapy;\n3. Patients without a baseline assessment of tumor burden undertaken prior to initiating T-DXd.\n4. Patient is participating in a clinical trial at time of enrolment","ALL","130 Years",{"count":64,"type":22},100,"OBSERVATIONAL","This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US",[68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,28,89,90,91,92,93],"Adenocarcinoma (NOS)","Anal Cancer","Bladder Cancer","Cervical Cancer","Endometrial Cancer","Esophageal Cancer","Gall Bladder Cancer","Gastrointestinal Stromal Tumour","Head and Neck Cancer","Liver Cancer","Melanoma","Mouth Cancer","Nasopharangeal Cancer","Neuroendocrine, Gastrointestinal Cancer","Ovarian Cancer","Pancreatic Cancer","Prostate Cancer","Renal Cell Carcinoma","Salivary Gland Cancer","Sarcoma","Small Cell Lung Cancer","Throat Cancer","Thyroid Cancer","Urethral Cancer","Vaginal Cancer","Vulvar Cancer","RECRUITING","2026-06-26",{"date":97,"type":44},"2026-06-29",{"date":99,"type":44},"2025-09-18",{"date":101,"type":22},"2028-03-30",{"name":103,"class":104},"AstraZeneca","INDUSTRY",17,{"id":107,"slug":108,"hasResults":12,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":113,"sex":61,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":118,"studyType":65,"phases":4,"briefSummary":119,"conditions":120,"keywords":156,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":174},"100210159","integrated-cancer-repository-for-cancer-research-100210159","NCT02012699","Integrated Cancer Repository for Cancer Research","iCaRe2","Inclusion Criteria\n\n* Diagnosis\u002Fhistory of cancer\n* Risk for developing cancer or suspicious clinical findings\n* No history of cancer (normal control registry)\n* Able to provide informed consent\n* 19 years of age or older\n* English or Spanish speaking individuals\n\nExclusion Criteria\n\n* Unable to provide informed consent because of cognitive impairment\n* Non-English or non-Spanish speaking individuals",true,"19 Years","110 Years",{"count":117,"type":22},999999,"80 Years","The iCaRe2 is a multi-institutional resource created and maintained by the Fred \\& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.",[83,90,121,73,122,123,124,125,69,126,127,128,129,77,130,131,132,133,70,134,135,84,28,136,91,137,138,139,140,141,142,143,144,86,145,146,147,148,149,150,78,87,151,152,82,72,92,153,154,155],"Lung Cancer","Thymus Cancer","Colon Cancer","Rectal Cancer","Gastrointestinal Stromal Tumors","Bile Duct Cancer","Duodenal Cancer","Gallbladder Cancer","Gastric Cancer","Small Intestine Cancer","Peritoneal Surface Malignancies","Familial Adenomatous Polyposis","Lynch Syndrome","Kidney Cancer","Penile Cancer","Ureter Cancer","Hypopharyngeal Cancer","Laryngeal Cancer","Lip Cancer","Oral Cavity Cancer","Nasopharyngeal Cancer","Oropharyngeal Cancer","Paranasal Sinus Cancer","Nasal Cavity Cancer","Skin Cancer","Central Nervous System Tumor","Central Nervous System Cancer","Mesothelioma","Breast Cancer","Leukemia","Unknown Primary Tumor","Multiple Myeloma","Neuroendocrine Tumors","Plasma Cell Dyscrasia","Healthy Control",[83,90,157,158,159,160,161,162,163,164,149,165,154,155],"Esophageal cancer","Thymus cancer","Pancreatic tumor","Esophageal tumor","Thymus tumor","Thyroid Tumor","Thyroid Nodule","Lung Tumor","Neuroendocrine tumor","2026-06-25",{"date":97,"type":44},{"date":169,"type":44},"2013-11-01",{"date":171,"type":22},"2099-12",{"name":173,"class":51},"University of Nebraska",42,{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":23,"phases":186,"briefSummary":187,"conditions":188,"keywords":190,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":205},"100570080","virtual-testis-cancer-lay-support-and-survivorship-aim-2-100570080","NCT06702592","Virtual Testis Cancer Lay Support and Survivorship Aim 2","Virtual Testicular Cancer Lay Support and Survivorship (VITALSS Study) Aim 2","VITALSS","Inclusion Criteria:\n\n* Men within 5 years of their initial diagnosis of germ cell testicular cancer.\n* The subject is willing and able to comply with study procedures based on the judgment of the investigator.\n* Adults aged 18-95 years old.\n* Electronic informed consent was obtained to participate in the study.\n\nExclusion Criteria:\n\n* Woman gender\n* Non-English speaking\n* Unwilling or unable to complete informed consent.\n* On active treatment for another cancer.\n* Actively receiving chemotherapy, radiation, or surgery for testicular cancer.","95 Years",{"count":185,"type":22},360,[25],"This study examines how virtual support can enhance well-being and survivorship in men with testicular cancer. Participants in North Carolina will be randomized into two groups: one with access to a virtual support platform and the other with access to patient educational materials only. After six months, the emotional well-being, self-efficacy, financial toxicity, and quality of life of both groups will be compared at 3 months and 6 months after baseline assessments.",[28,189],"Testis Cancer",[191,192,193,194,195],"virtual support","emotional well-being","self-efficacy","financial toxicity","quality of life","2026-06-22",{"date":198,"type":44},"2026-06-23",{"date":200,"type":22},"2026-07",{"date":202,"type":22},"2028-06",{"name":204,"class":51},"UNC Lineberger Comprehensive Cancer Center",1,{"id":207,"slug":208,"hasResults":12,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":12,"sex":61,"minAge":19,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":23,"phases":214,"briefSummary":217,"conditions":218,"keywords":221,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":205},"100624280","phase-1-ph-iii-sodium-thiosulfate-for-otoprotection-during-cisplatin-stop-cis-100624280","NCT07407582","Ph. I\u002FII Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)","Phase I\u002FII Open Label Trial of Intravenous Sodium Thiosulfate (Pedmark®) as Otoprotectant in Adults Receiving Cisplatin Chemotherapy (STOP-CIS)","Inclusion Criteria:\n\n* Participants have provided informed consent prior to initiation of any study-specific activities.\n* At least 18 years of age, male or female, at the time of signing the informed consent.\n* ECOG Performance Status 0-1\n* Histologically or cytologically confirmed treatment-naïve cancer.\n* Scheduled to receive an FDA-approved, on-label indication, standard of care systemic cisplatin-based regimen (at least 200 mg\u002Fm2 cumulative dose) for any untreated any solid malignancy deemed by the treating physician\n\nExclusion Criteria:\n\n* Prior cisplatin exposure due to a cancer treatment history\n* Concurrent ototoxic medication unable to be safely discontinued or switched to a non-toxic alternative\n* Planned radiation to the head or neck prior to, during, or within 3 months of completion of cisplatin\n* History of severe hypersensitivity to sulfite, sodium thiosulfate, or any components\n* Baseline serum sodium \\> 145 mmol\u002FL or any grade ≥ 3 electrolyte abnormality\n* Cisplatin infusion duration greater than 6 hours\n* Females during pregnancy or breastfeeding, and childbearing potential, unwilling to use a method of contraception during treatment\n* Male subjects with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment\n* Subject likely not to be available to complete all protocol-required study visits or procedures, and\u002For to comply with all required study procedures (i.e., Clinical Outcome Assessments) to the best of the subject's and investigator's knowledge.\n* History or evidence of any other clinically significant disorder, condition, or disease (with the exception of those outlined above) that, in the opinion of the investigator, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.",{"count":7,"type":22},[215,216],"PHASE1","PHASE2","The purpose of this study is to assess the safety and effectiveness of a drug called Pedmark® sodium thiosulfate (STS) in reducing hearing impairment with standard of care cisplatin therapy. The safety and effectiveness of STS in reducing hearing loss has been well established in children and is approved for use in the pediatric and young adult population. However, information in adult patients is limited. As most cisplatin is administered in the adult population, this investigation would be of benefit.",[219,28,76,220],"Solid Tumor Malignancies","Thoracic Cancer",[222,223,224,225,226,227,228],"Cisplatin","Otoprotectant","Cancer","Hearing Impairment","Sodium Thiosulfate","Adults","Solid Tumor","2026-06-16",{"date":231,"type":44},"2026-06-18",{"date":233,"type":44},"2026-05-18",{"date":235,"type":22},"2028-04-30",{"name":237,"class":51},"University of Arizona",{"id":239,"slug":240,"hasResults":12,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":12,"sex":61,"minAge":19,"maxAge":4,"enrollmentInfo":245,"targetDuration":4,"studyType":23,"phases":247,"briefSummary":248,"conditions":249,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":259},"100555709","phase-1-a-phase-1-study-of-ctim-76-in-patients-with-recurring-ovarian-cancer-and-other-advanced-solid-tumors-100555709","NCT06515613","A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors","A Phase 1, First in Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors","Inclusion Criteria:\n\n* Participants with CLDN6 positive platinum resistant\u002Frefractory ovarian, advanced testicular or advanced endometrial cancer.\n* Participants with measurable disease per RECIST 1.1.\n* ECOG 0, 1, or 2 and life expectancy of ≥ 12 weeks.\n* Participants with adequate organ function.\n\nExclusion Criteria:\n\n* Evidence of central nervous system metastases, leptomeningeal disease or spinal cord compression.\n* Uncontrolled significant active infection or any medical or other condition that in opinion of the Investigator would preclude the participant's participation in the study.\n* Concurrent participation in another investigational clinical trial.",{"count":246,"type":22},156,[215],"This is a Phase 1a\u002F1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with platinum-refractory\u002Fresistant ovarian cancer (PRROC) and other advanced CLDN6-positive solid tumors (i.e., testicular and endometrial).",[250,28,72],"Platinum-resistant Ovarian Cancer","2026-06-15",{"date":229,"type":44},{"date":254,"type":44},"2024-07-10",{"date":256,"type":22},"2028-12-31",{"name":258,"class":104},"Context Therapeutics Inc.",14,{"id":261,"slug":262,"hasResults":12,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":12,"sex":61,"minAge":19,"maxAge":268,"enrollmentInfo":269,"targetDuration":4,"studyType":23,"phases":271,"briefSummary":272,"conditions":273,"keywords":281,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":291},"100578684","phase-1-radiation-combined-with-bispecific-t-cell-engager-in-dll3-expressing-tumors-100578684","NCT06814496","Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors","RAdiation comBined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Study: A Phase I\u002FII Study of AMG757 \u002F Tarlatamab and Concurrent Radiation Therapy in Tumors With High Prevalence of DLL3","RABBIT","Inclusion Criteria:\n\n1. Subject has provided informed consent\u002Fassent prior to initiation of any study specific activities\u002Fprocedures.\n2. Subjects ≥ 18 years of age at the time of signing the informed consent.\n3. Histologically or cytologically confirmed relapsed\u002Frefractory:\n\n   1. SCLC\n   2. Other tumors of small cell histology\n   3. High grade \u002F poorly differentiated neuroendocrine histology tumor histologies with high prevalence of DLL3 (≥50% prevalence of ≥1% positivity), including but not limited to: melanoma, medullary thyroid cancer, esthesioneuroblastoma, bladder cancer, testicular cancer, glioblastoma multiforme, cervical cancer; large cell neuroendocrine tumor of lung, non-small cell lung cancers with mixed neuroendocrine features, and Merkel cell carcinoma OR\n   4. DLL3+ (≥1% by IHC) Note: If patients are DLL3 negative per IHC but have a DLL3 prevelant tumor type, they will be allowed to enroll on the study.\n4. Subjects who progressed or recurred after at least one line of therapy and are considered treatment refractory per standard of care.\n5. Subjects willing to provide archived tumor tissue samples (formalin fixed, paraffin embedded \\[FFPE\\] sample). If no archived tumor tissue is available, we request to undergo pretreatment tumor biopsy. Subjects who do not have archived tumor tissue available and are unable or unwilling to undergo a pretreatment tumor biopsy due to extenuating circumstances (i.e., cannot be performed safely or inaccessible, as determined by the investigator) may be allowed to enroll without a tumor biopsy upon agreement with sponsor.\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.\n7. Minimum life expectancy of 12 weeks.\n8. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen.\n9. Measurable lesions as defined per RECIST 1.1 within 28 days prior to the first dose of tarlatamab.\n10. Eligible for external beam radiation therapy to a previously unirradiated, measurable lesion as per standard of care.\n\n    1. For the concurrent \u002F sequential cohort of extracranial RT sites:\n\n    i. A minimum of 10 subjects with thoracic lesions (lung, mediastinum, thoracic spine, rib, or other thoracic sites) will be treated ii. Subjects with treated brain metastases are eligible (untreated brain metastases are ineligible) provided they meet the following criteria:\n\n\u003C!-- -->\n\n1. Definitive therapy was completed at least 2 weeks prior to the first dose of tarlatamab.\n2. There is no evidence of radiographic central nervous system (CNS) progression following therapy and by the time of study screening.\n3. Patients manifesting progression in lesions previously treated with stereotactic radiosurgery may still be eligible if pseudoprogression can be demonstrated by appropriate means.\n4. Any CNS disease is asymptomatic for at least 7 days (unless symptoms are deemed irreversible by the investigator), the patient is off steroids for at least 7 days (physiologic doses of steroids are permitted), and the subject is off or on stable doses of anti-epileptic drugs for malignant CNS disease for at least 7 days.\n\n   b. For the concurrent\u002Fsequential cohort of cranial RT sites: i. Previously untreated brain lesions \u002F metastases are eligible ii. Subjects with previously irradiated brain lesions are eligible provided they meet one of the following criteria:\n\n\u003C!-- -->\n\n1. Prior PCI or whole brain radiation therapy per standard of care with new and\u002For recurrent brain metastases to be treated with SRS or hfSRT\n2. Prior course(s) of SRS or hfSRT or other localized therapy with new lesion(s) to be treated with whole brain radiation therapy iii. Whole brain re-irradiation will be ineligible iv. Re-irradiation with SRS or hfSRT of previously irradiated lesion with SRS or hfSRT will be ineligible v. Craniospinal irradiation will not be allowed c. For the tarlatamab monotherapy cohort: i. Patient must have at least one measurable lesion, however that lesion does not need to be amenable to RT\n\n1\\. Patients with previously irradiated lesions that have recurred or progressed are eligible 11. Adequate organ function, defined as follows:\n\na. Hematological function: i. Absolute neutrophil count ≥ 1.5 x 109\u002FL ii. Platelet count ≥ 100 x 109\u002FL iii. Hemoglobin \\> 9 g\u002FdL (90 g\u002FL) b. Coagulation function: i. Prothrombin time (PT)\u002Finternational normalized ratio (INR) and partial thromboplastin time (PTT) or activated partial thromboplastin time (APTT) ≤ 1.5 x institutional upper limit of normal (ULN). Subjects on chronic anticoagulation therapy who do not meet the criteria above may be eligible to enroll after discussion with the medical monitor.\n\nc. Renal function: i. Estimated glomerular filtration rate (eGFR) based on Modification of Diet in Renal Disease (MDRD) calculation \\> 30 mL\u002Fmin\u002F1.73 m2 d. hepatic function: i. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) \\\u003C 3 x ULN (or \\\u003C 5 x ULN for subjects with liver involvement) ii. Total bilirubin \\\u003C 1.5 x ULN (or \\\u003C 2 x ULN for subjects with liver metastases) e. Pulmonary function: i. No clinically significant pleural effusion ii. Baseline oxygen saturation \\> 90% on room air f. cardiac function (if obtained as part of standard of care): i. Cardiac ejection fraction ≥ 50%, no clinically significant pericardial effusion as determined by an echocardiogram (ECHO) or multigated acquisition (MUGA) scan, and no clinically significant electrocardiogram (ECG) findings\n\nExclusion Criteria:\n\nRe-irradiation, unless it is SRS\u002FhfSRT after whole-brain radiation therapy (WBRT) or PCI or WBRT after SRS\u002FhfSRT; re-irradiation of same lesion, unless verified with the Principal Investigator; patients with lesions not amenable to RT (including previously irradiated) will be only allowable on the tarlatamab monotherapy cohort.\n\nDisease Related\n\n1. Subjects are excluded from the study if any of the following criteria apply:\n\n   1. No lesion(s)\u002Fsite(s) amenable to radiation therapy (only eligible for tarlatamab monotherapy if open)\n   2. Planned re-irradiation of a previously irradiated site\n   3. Leptomeningeal disease requiring craniospinal irradiation\n2. Has evidence of interstitial lung disease or active, non-infectious pneumonitis.\n3. Subjects who experienced recurrent pneumonitis (grade 2 or higher) or severe, life-threatening immune-mediated adverse events or infusion-related reactions including those that lead to permanent discontinuation while on treatment with immuno-oncology agents.\n4. Unresolved toxicity from prior anti-tumor therapy, defined as not having resolved to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grade 1, or to levels dictated in the eligibility criteria with the exception of alopecia or toxicities from prior anti-tumor therapy that are considered irreversible (defined as having been present and stable for \\> 21 days) which may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and Amgen.\n\nOther Medical Conditions\n\n1. Myocardial infarction and\u002For symptomatic congestive heart failure (New York Heart Association \\> class II) within 12 months of first dose of tarlatamab.\n2. History of arterial thrombosis (i.e., stroke or transient ischemic attack) within 12 months of first dose of tarlatamab.\n3. Subject with symptoms and\u002For clinical signs and\u002For radiographic signs that indicate an acute and\u002For uncontrolled active systemic infection within 7 days prior to the first dose of tarlatamab.\n\n   NOTE: Simple urinary tract infection and uncomplicated bacterial pharyngitis are permitted if responding to active treatment. Subjects requiring oral antibiotics who have been afebrile \\> 24 hours, have no leukocytosis and have no clinical signs of infection are eligible. Subjects who meet these criteria and who were previously on IV antimicrobials should have been off IV antimicrobials for \\> 48 hours.\n4. History of hypophysitis or pituitary dysfunction.\n5. Exclusion of hepatitis infection based on the following results and\u002For criteria:\n\n   a. Positive for hepatitis B surface antigen (HBsAg) (indicative of chronic hepatitis B or recent acute hepatitis B).\n\n   b. Negative HBsAg and positive for hepatitis B core antibody: hepatitis B virus DNA by polymerase chain reaction (PCR) is necessary. Detectable hepatitis B virus DNA suggests occult hepatitis B.\n\n   c. Positive hepatitis C virus antibody (HCVAb): hepatitis C virus RNA by PCR is necessary. Detectable hepatitis C virus RNA suggests chronic hepatitis C.\n6. Major surgery requiring hospitalization for more than 3 days within 28 days of first dose of tarlatamab.\n7. Evidence of interstitial lung disease or active, non-infectious pneumonitis.\n8. Active autoimmune disease that has required systemic treatment (except replacement therapy) within the past 2 years or any other diseases requiring immunosuppressive therapy while on study.\n9. Human immunodeficiency virus (HIV) infection.\n\n   1. Subjects with HIV infection on antiviral therapy and undetectable viral load are permitted with a requirement for regular monitoring for reactivation for the duration of treatment on study per local or institutional guidelines.\n\nPrior\u002FConcomitant Therapy\n\n1. Subject received prior therapy with tarlatamab.\n2. Prior anti-cancer therapy within 30 days prior to first dose of tarlatamab.\n\n   Exceptions:\n\n   a. Subjects who received conventional chemotherapy are eligible if at least 14 days have elapsed and if all treatment-related toxicity has been resolved to grade ≤ 1.\n3. Has a diagnosis of immunodeficiency (i.e., positive\u002Fnon-negative test for human immunodeficiency virus) or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of tarlatamab.\n4. The following vaccines (live and live-attenuated vaccines) are excluded during the following study periods:\n\n   1. Screening and during study treatment: Live and live-attenuated vaccines are prohibited within 28 days prior to the first dose of tarlatamab and for the duration of the study.\n   2. Live viral non-replicating vaccine (i.e., Jynneos) for Monkeypox infection is allowed during the study (except during cycle 1) in accordance with local standard of care (SOC) and institutional guidelines.\n   3. End of study treatment: Live and live-attenuated vaccines can be used when at least 60 days (5 x half-life of tarlatamab) have passed after the last dose of tarlatamab.\n\nOther Exclusions\n\n1\\. Female subjects of childbearing potential unwilling to use protocol specified method of contraception during treatment and for an additional 60 days after the last dose of tarlatamab. Contraception methods for female subjects include:\n\n1. Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal)\n2. Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, and implantable)\n3. Intrauterine device\n4. Intrauterine hormonal-releasing system\n5. Bilateral tubal ligation\u002Focclusion\n6. Vasectomized partner (provided that partner is the sole sexual partner of the female subject of childbearing potential and that the vasectomized partner has received medical assessment of the surgical success)\n7. Sexual abstinence (defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments; the reliability of sexual abstinence must be evaluated in relation to the duration of the trial and the preferred and usual lifestyle of the subject) 2. Female subjects who are breastfeeding or who plan to breastfeed while on study through 60 days after the last dose of tarlatamab.\n\n   3\\. Female subjects planning to become pregnant while on study through 60 days after the last dose of tarlatamab.\n\n   4\\. Female subjects of childbearing potential with a positive pregnancy test assessed at screening and\u002For day 1 by a highly sensitive urine or serum pregnancy test.\n\n   5\\. Male subjects with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception (use a condom) during treatment and for an additional 60 days after the last dose of tarlatamab.\n\n   6\\. Male subjects with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment and for an additional 60 days after the last dose of tarlatamab.\n\n   7\\. Male subjects unwilling to abstain from donating sperm during treatment and for an 60 days after the last dose of tarlatamab.\n\n   8\\. Subject has known sensitivity to any of the products or components to be administered during dosing.\n\n   9\\. Subject likely to not be available to complete all protocol-required study visits or procedures, and\u002For to comply with all required study procedures (i.e., Clinical Outcome Assessments) to the best of the subject and investigator's knowledge.\n\n   10\\. History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures, or completion.","99 Years",{"count":270,"type":22},30,[215,216],"Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites.\n\nI) After lead in of 10 patients demonstrating safety of treatment, allow for expansion to cranial sites of disease (N=6-10) with continued enrollment in main cohort II) If toxicity criteria is not met in concurrent RT tarlatamab cohort, we will continue with sequential RT, either A) delivered within 7 days prior to cycle 1 day 1, or B) delivered during cycle 1 -2 but with pre- and post-RT washout of 7 days with no drug during RT, to examine safety in a temporally spaced setting.\n\nIII) If sequential tarlatamab and radiation is not deemed safe, we would allow for continued enrollment to assess efficacy of drug sans radiation treatment, enriching for tumors not of small cell lung cancer histology and allowing for patients without sites amenable to RT.\n\nA nested phase II study will attempt to assess for ORR and safety of study intervention amongst tumors not of small cell lung cancer histology.",[78,274,275,276,70,28,277,71,278,279,280],"Medullary Thyroid Cancer","Sinonasal Undifferentiated Carcinoma","Esthesioneuroblastoma","Glioblastoma Multiforme","Large Cell Neuroendocrine Carcinoma of the Lung","Non Small Cell Lung Cancer","Merkel Cell Carcinoma",[282],"DLL3 Expressing tumors","2026-05-19",{"date":285,"type":44},"2026-05-20",{"date":287,"type":44},"2025-09-08",{"date":289,"type":22},"2030-05",{"name":237,"class":51},2,{"id":293,"slug":294,"hasResults":12,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":4,"eligibilityCriteria":298,"healthyVolunteers":12,"sex":61,"minAge":19,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":23,"phases":301,"briefSummary":302,"conditions":303,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":205},"100567833","phase-1-brodalumab-in-the-treatment-of-immune-related-adverse-events-100567833","NCT06673329","Brodalumab in the Treatment of Immune-Related Adverse Events","Safety and Efficacy of Brodalumab in the Treatment of Immune-Related Adverse Events: A Pilot Study","Inclusion Criteria:\n\n* Ability to provide written informed consent by subject or guardian\n* Individuals \\>18 years of age\n* Diagnosis of an irAE clinically suspected to be IL-17 mediated\n* Intent-to-treat or prior treatment with systemic steroids for irAE management\n* Histology-proven primary advanced or metastatic solid organ malignancy treated with immunotherapy. Patients being treated with curative intent are not eligible to enroll.\n* Subject has a negative test for tuberculosis during screening defined as either: negative purified protein derivative (PPD) (\\\u003C 5 mm of induration at 48 to 72 hours after test is placed) OR negative QuantiFERON test. Tuberculosis testing must be performed within 30 days prior to trial initiation.\n* Subjects with a positive PPD and a history of Bacillus Calmette-Guérin vaccination are allowed with a negative QuantiFERON test.\n* Subjects with a positive PPD test (without a history of Bacillus Calmette-Guérin vaccination) or subjects with a positive or indeterminate QuantiFERON test are allowed if they have all of the following: no symptoms of tuberculosis (defined as fever, shortness of breath, cough or night sweats), documented history of a completed course of adequate prophylaxis (per local standard of care), no known exposure to a case of active tuberculosis after most recent prophylaxis, no evidence of active tuberculosis on chest radiograph within 3 months prior to the first dose of brodalumab.\n\nExclusion Criteria:\n\n* Estimated creatinine clearance \\\u003C 40 mg\u002Fmin\n* Active suicidal ideation or severe depression (as defined by the Diagnostic and Statistical Manual of Mental Disorders Version IV criteria (DSM-IV)) at the time of enrollment or a PHQ-9 score \\> 20\n* History of prior suicide attempts\n* PHQ-9 score greater \\>5 and \\\u003C 20 without an established mental health provider who verifies stability in their depression\n* Current or prior drug or alcohol abuse within the past 6 months (as defined by the DSM IV)\n* In the opinion of the investigator, the patient requires additional immunosuppressive treatment (other than corticosteroids and brodalumab)\n* Known hypersensitivity or contraindication to brodalumab, corticosteroids or any components of brodalumab\n* Prior treatment with brodalumab\n* Pregnancy, breastfeeding, or use of a nonreliable method of contraception\n\n  * For patients assigned female at birth: lack of willingness to use highly effective methods of birth control during treatment and for at least 4 weeks after the last dose of brodalumab (except if surgically sterile or at least 2 years postmenopausal, with postmenopausal status confirmed by Follicle-Stimulating Hormone (FSH) in the postmenopausal range).\n  * Highly effective methods of birth control include: use of hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. Oral contraceptive pills must be supplemented by a barrier method.\n  * Patients planning to become pregnant while enrolled in the study and within 4 weeks after the last dose of brodalumab will not be permitted to enroll\n* Chronic or current severe infection requiring IV therapy\n* Evidence of active hepatitis B, C, or tuberculosis.\n* History of latent tuberculosis infection which is incompletely treated based upon local standard of care or which was never treated\n* History of or active Crohn's disease.\n* Myocardial infarction, unstable angina pectoris or stroke within the past 12 months prior to the first investigational product dose\n* Any concurrent medical condition or electrocardiogram (ECG) abnormality that, in the opinion of the investigator, could cause this study to be detrimental to the subject.\n* Any medical condition or treatment for a condition that, in the opinion of the investigator, might interfere with participation in the study or affect the reliability of clinician assessment or patient self-report\n* Other known clinically significant active medical conditions, such as:\n\n  * Severe cardiovascular disease, including advanced heart failure (American Heart Association Stage D)\n  * Aspartate aminotransferase (AST) and or alanine aminotransferase (ALT) greater than 2 times the upper limit of normal or greater than 3 times the upper limit of normal in patients with liver metastases measured on at least two separate occasions\n  * Direct bilirubin greater than or equal to 1.5 mg\u002FdL in patients with or without liver metastases\n  * Bone marrow insufficiency unrelated to the irAE (according to investigator judgment) with White Blood Cell (WBC) \\\u003C2000\u002Fmm3, absolute neutrophil count \\\u003C1500\u002F mm3, thrombocytopenia (platelet count) \\\u003C50,000\u002Fmm3, hemoglobin \\\u003C 8.0 g\u002FdL\n* Plan to proceed with further curative intent treatment for cancer at the time of enrollment despite the presence of irAE\n* Participation in another therapeutic clinical trial and receipt of investigational drugs within 4 weeks before the screening visit\n* Previous diagnosis of an autoimmune disease or administration of immunosuppressants in a time frame that would impede interpretation of brodalumab administration\n* Planned use of immunosuppressive agents other than steroids (including infliximab, vedolizumab, tocilizumab etc.) or administration of such agents within 28 days of trial initiation\n* Administration of live-virus vaccines within 4 weeks before the first dose of brodalumab",{"count":300,"type":22},11,[215],"The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who previously received immunotherapy and the goal of this study is to help better control these side effects. Brodalumab is often used to treat patients with autoimmune diseases (diseases where the immune system is activated against normal organs) and safe doses and treatment schedules have been determined in these patients. Immune-related side effects appear to closely mirror these autoimmune conditions. Brodalumab has not been approved by the United States Food and Drug Administration (FDA) for use in immunotherapy side effects but it has been approved for treatment of autoimmune conditions.",[149,73,134,121,90,304,83,305,306,123,124,76,307,77,145,84,28,228],"Gynecologic Cancer","Stomach Cancer","Brain Tumor","Oral Cancer","2026-05-11",{"date":310,"type":44},"2026-05-13",{"date":312,"type":44},"2025-03-11",{"date":314,"type":22},"2027-11",{"name":316,"class":51},"Brian Henick, MD",{"id":318,"slug":319,"hasResults":12,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":323,"eligibilityCriteria":324,"healthyVolunteers":12,"sex":18,"minAge":325,"maxAge":326,"enrollmentInfo":327,"targetDuration":4,"studyType":23,"phases":329,"briefSummary":330,"conditions":331,"keywords":334,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":4},"100636885","helping-young-people-with-testicular-cancer-using-virtual-and-extended-reality-100636885","NCT07571499","Helping Young People With Testicular Cancer Using Virtual and Extended Reality","Addressing TesticulaR cANcer Unmet Supportive CarE NeeDs in Adolescents and Young Adults Using eXtended Reality","TRANSCEND-XR","Inclusion Criteria:\n\n1. Any person assigned male at birth who is diagnosed with stage I-III TC (germ cell tumour of the testicles).\n2. Aged between 15 and 39 years at the time of study inclusion.\n3. Completed curative treatment comprising of at least one standard treatment modality (surgery, chemotherapy and\u002For radiotherapy) for treatment of their cancer. A maximum of 9 months from the end of curative treatment will be allowed.\n4. Permitted treatment modalities:\n\n   * Localised disease: orchiectomy with or without chemotherapy and\u002For radiotherapy.\n   * Metastatic disease: orchiectomy and chemotherapy or radiotherapy or retroperitoneal surgery, or a combination of aforementioned treatments. First-line treatment only allowed.\n5. Willing and able to provide a valid and signed informed consent and\u002For assent, as appropriate.\n6. ECOG performance status 0-2.\n7. Patients accept to use personal smartphone\n8. Patients able to read and understand the local language\n\nExclusion Criteria:\n\n1. Non-testicular germ cell tumours (e.g., mediastinal primary or retroperitoneal primary tumours).\n2. Non-germ cell TC.\n3. Previous chemotherapy, radiotherapy, or surgery for TC other than that allowed in IC 4.\n4. History of contralateral TC.\n5. Any illness that would prevent the AYA TC survivor from giving a valid and signed informed consent, as assessed by the investigator.\n6. Any illness that might be exacerbated by the use of an XR digital tool, as assessed by the investigator, including history of severe motion sickness, brain lesions and epilepsy.\n7. Uncontrolled medical condition such as uncontrolled infection, uncontrolled diabetes mellitus or cardiac disease (including but not limited to grade 2 or higher cardiac failure, arrythmia, unstable angina, history of myocardial infract in the 6 months which, in the opinion of the treating physician, would influence the assessment of long-term side effect of TC treatment.\n8. AYA TC survivors with a \"currently active\" second malignancy other than non-melanoma skin cancers, superficial non-invasive (pTa or pTis) TCC of the bladder, or intratubular germ cell neoplasia. Patients are not considered to have a \"currently active\" malignancy if they have completed therapy and are free of disease for ≥ 3 years.\n9. Chemotherapy or radiotherapy for malignant disease other than TC within the past 3 years.","15 Years","39 Years",{"count":328,"type":22},245,[25],"TRANSCEND-XR is a European research project designed to better support adolescents and young adults who have been cured of testicular cancer. Even after treatment has ended, many young people continue to face physical, psychological, or social difficulties that are often poorly understood and insufficiently addressed.\n\nThe project aims to develop an innovative digital tool using extended reality (XR) to help these young people better understand the potential long-term effects of the disease and its treatments, recognize signs that require medical attention, and become more active participants in their own health follow-up.\n\nTRANSCEND-XR first includes a pilot phase to test feasibility and improve the tool, followed by a larger clinical study comparing its use with usual medical follow-up. Researchers will assess, in particular, its impact on patients' knowledge, quality of life, and ability to seek help.\n\nThe ultimate goal is to sustainably improve information, autonomy, and well-being among young survivors of testicular cancer through a digital approach tailored to their needs and daily practices.",[28,189,332,333],"AYA Cancer Survivors","Survivor Patients",[335,336,337,338,339,340,341,342,343,344,345,346,347],"Testicular cancer survivors","Adolescents and young adults (AYA)","Survivorship care","Supportive care needs","Late effects of cancer treatment","Post-cancer follow-up","Quality of life","Patient education","Extended reality (XR)","Virtual reality in healthcare","Digital health intervention","Immersive digital tools","Long-term cancer effects","2026-04-30",{"date":350,"type":44},"2026-05-06",{"date":352,"type":22},"2027-01-04",{"date":354,"type":22},"2029-06-30",{"name":356,"class":51},"Gustave Roussy, Cancer Campus, Grand Paris",{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":12,"sex":61,"minAge":19,"maxAge":364,"enrollmentInfo":365,"targetDuration":4,"studyType":23,"phases":367,"briefSummary":368,"conditions":369,"keywords":371,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":205},"100530944","digital-peer-navigation-for-adolescents-and-young-adults-with-cancer-100530944","NCT06193369","Digital Peer Navigation for Adolescents and Young Adults With Cancer","Digital Peer Navigation for Adolescents and Young Adults With Cancer: A Feasibility Study","Inclusion criteria:\n\n1. Are 18-40 years old;\n2. Were diagnosed with breast or testicular cancer, lymphoma or sarcoma between the ages of 15-39 years old;\n3. Have completed therapy within the last 12 months;\n4. Are comfortable using the internet;\n5. Have an active email address OR are willing to create one;\n6. Able to read and speak English.\n\nExclusion criteria:\n\n1. Have metastatic disease or are receiving palliative end-of-life care;\n2. Are not willing to be randomized.","40 Years",{"count":366,"type":22},138,[25],"Adolescents and young adults (AYA) diagnosed with cancer experience unique challenges after completing treatment and face distinct barriers to optimal care and support. These challenges include higher levels of symptom burden and treatment complications, interrupted education, careers and relationships, and financial hardship. AYA lack access to peers, relevant information and emotional support, and report gaps in care when dealing with these difficult challenges.\n\nDigital peer navigation could help to address the needs of AYA and overcome barriers to care and support. The PI developed True North Peer Navigation (TrueNTH-PN), an evidence-based digital peer navigation program for men with prostate cancer and online peer navigator training course. The goal of this project is to adapt TrueNTH-PN for AYA and evaluate its feasibility to overcome barriers to care and support, and enhance patient activation among AYA during the challenging post-treatment phase.\n\nIn partnership with AYA cancer survivors, the Canadian Cancer Society, Young Adult Cancer Canada, a digital app design firm and technology provider, our cross-Canada team will: (1) Adapt and evaluate the usability of the TrueNTH-PN app for AYA; (2) Adapt and evaluate the effectiveness of the Peer Navigator Training Course for AYA; and (3) Determine the feasibility, acceptability and preliminary effectiveness of the new AYA-PN program among post-treatment AYA cancer survivors.\n\nThis project will produce an innovative solution to an important service gap in the lives of AYA with cancer. It has the potential to address the support needs of AYA, overcome barriers to care, and empower AYA to take proactive role in managing their health. In addition, it will give rise to AYA peer navigators with specialized skills, which could fill gaps in disrupted education and career paths, and help to attain future goals.",[370,149,28,87],"Lymphoma",[372,373,374,375,376,377,378],"Young Adults","Post-Treatment Cancer Survivorship","Digital Health","Patient Navigation","Peer Support","Patient Activation","Pilot RCT","2026-04-28",{"date":381,"type":44},"2026-05-04",{"date":383,"type":44},"2024-08-27",{"date":385,"type":22},"2026-12",{"name":387,"class":51},"University Health Network, Toronto",{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":394,"eligibilityCriteria":395,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":396,"targetDuration":4,"studyType":23,"phases":398,"briefSummary":399,"conditions":400,"keywords":405,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":205},"100631306","primary-rplnd-versus-systemic-chemotherapy-in-good-prognosis-metastatic-testicular-cancer-100631306","NCT07498959","Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer","Testicular Cancer Treatment: Assessing Quality of Life in Good Prognosis Metastastic Disease","TESTIGO","Inclusion Criteria:\n\n* Patients ≥18 years undergoing an open or minimally invasive primary retroperitoneal lymph node dissection (RPLND) due to seminoma stage II A\u002FB (maximum 2 nodes, \\\u003C30 mm in any dimension)\n* Patients undergoing an open or minimally invasive primary RPLND due to a retroperitoneal relapse of seminoma (maximum 2 nodes, \\\u003C30 mm in any dimension)\n* Patients ≥18 years scheduled for 3-4 courses of chemotherapy due to a newly diagnosed good-prognosis metastatic germ cell tumor (nonseminoma or seminoma)\n\nExclusion Criteria:\n\n* Previous chemotherapy (including adjuvant chemotherapy at diagnosis)\n* Previous RPLND\n* Practical considerations, such as not being able to read and sign informed consent or understand the questionnaires",{"count":397,"type":22},160,[25],"The goal of this prospective observational study is to learn about the short- and long-term effects of treating men over the age of 18 with good prognosis metastatic testicular cancer with either primary retropertioneal lymph node dissection, RPLND, (for low-stage metastastic seminoma) or three doses of chemotherapy for metastastic seminoma or nonseminoma. The main question it aims to answer is:\n\nDoes primary RPLND lower the risk of side-effects compared to receiving chemotherapy?",[28,401,402,403,404],"Seminoma","Quality of Life","De-escalation","RPLND",[406,407,408],"testicular cancer","seminoma","primary RPLND","2026-03-24",{"date":411,"type":44},"2026-03-27",{"date":413,"type":44},"2026-03-19",{"date":415,"type":22},"2032-03-25",{"name":417,"class":51},"Sahlgrenska University Hospital",{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":4,"eligibilityCriteria":424,"healthyVolunteers":12,"sex":61,"minAge":425,"maxAge":426,"enrollmentInfo":427,"targetDuration":4,"studyType":23,"phases":428,"briefSummary":429,"conditions":430,"keywords":433,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":4},"100624165","navigation-intervention-for-adolescent-and-young-adult-cancer-survivors-100624165","NCT07406087","Navigation Intervention for Adolescent and Young Adult Cancer Survivors","Adaptation and Implementation of an Evidence-Based Patient Navigation Intervention for Adolescent and Young Adult Cancer Survivors","Inclusion Criteria:\n\n* Received diagnosis of local or regional breast, ovarian, cervical, testicular, colon\u002Frectal, melanoma, endometrial, sarcoma, or thyroid cancer between the ages of 15-39 years (\"index cancer\")\n* Current age 21-45 years\n* Diagnosed and treated for index cancer within Kaiser Permanente Southern California\n* Current Kaiser Permanente insurance coverage\n\nExclusion Criteria:\n\n* Patients with a history of or current diagnosis of leukemia or lymphoma\n* Patients with metastatic disease at diagnosis","21 Years","45 Years",{"count":7,"type":22},[25],"The investigators propose to: 1) Adapt an evidence-based cancer-focused patient navigation (PN) program for the Adolescent and Young Adult (AYA) cancer survivor population; and 2) Plan and conduct an effectiveness-implementation trial of this program within Kaiser Permanente Southern California (KPSC). PLEASE NOTE: This study is awarded in two phases. The UG3 phase has been awarded for the first two years; upon successful completion of this phase by meeting pre-defined milestones, the National Cancer Institute (NCI) will provide funding for the second phase of the study (Years 3-6), which will allow our team to conduct a trial to determine the effectiveness of the implementation of the adapted PN program for the AYA cancer survivor population. This application is focused on the initial UG3 phase and will update the protocol for the UH3 trial upon successful completion of the UG3 milestones and receipt of the UH3 award.\n\nThe primary objectives in the UG3 phase of the study are to adapt and tailor an existing PN program to meet the needs of AYA cancer survivors and the local clinical context via (a) interviews with key stakeholders (patients, clinicians, administrators) and (b) guidance from our AYA Primary Care Survivorship Council. The investigators will conduct a pilot study of the adapted PN program and refine the program to enhance acceptability to patients and clinicians, enhance feasibility and effectiveness, and develop and pilot evaluation tools and methods prior to the start of the UH3 phase of the trial, which will be a larger trial. Objectives will be updated for the UH3 phase once awarded.",[149,82,71,28,431,432,72,87,90],"Colon Rectal Cancer","Melanoma (Skin Cancer)",[434,435,375,436,437],"Adolescent and Young Adult","Cancer Survivors","Adaptations","Implementation Science","2026-02-23",{"date":440,"type":44},"2026-02-25",{"date":442,"type":22},"2026-11-01",{"date":444,"type":22},"2027-08",{"name":446,"class":51},"Kaiser Permanente",{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":404,"eligibilityCriteria":453,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":118,"enrollmentInfo":454,"targetDuration":4,"studyType":23,"phases":456,"briefSummary":458,"conditions":459,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":291},"100561707","phase-3-intrathecal-morphine-versus-intravenous-methadone-for-postoperative-analgesia-following-retroperitoneal-lymph-node-dissection-100561707","NCT06593665","Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection.","Randomized Prospective Study Comparing Intrathecal Morphine vs Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection (RPLND)","Inclusion Criteria:\n\n* Patients undergoing a virgin (chemotherapy has not been used) or post- chemotherapy retroperitoneal lymph node dissection for primary testicular cancer at IU Health AAHC\n* ASA Class 1, 2, 3\n* Age 18 to 80 years; Male\n* BMI less than 50kg\u002Fm2\n\nExclusion Criteria:\n\n* Any contraindication for neuraxial analgesia\n* Patient on home methadone at any dose\n* Any physical, mental or medical conditions which, in the opinion of the investigators, may confound quantifying postoperative pain resulting from surgery.\n* Known true allergy to the study medications (morphine, bupivacaine, acetaminophen, methadone)\n* Any history of substance abuse in the past 6 months which would include heroin or any other illegal street drugs\n* End stage liver disease, end stage renal disease\n* Patient staying intubated after surgery\n* Patient (home dose) taking more than 30mg PO morphine equivalent (PME) per day\n* Any additional surgical procedures to the patient with a different surgical incision compared to the standard laparotomy for the RPLND procedure, i.e. thoracic tumor reduction",{"count":455,"type":22},142,[457],"PHASE3","This randomization study is to compare both intrathecal morphine and intravenous methadone, which are both standard of care, for pain management in patients undergoing retroperitoneal lymph node dissections for primary testicular cancer. Investigators plan to compare their analgesic effectiveness at different postoperative time intervals.",[28],"2026-02-11",{"date":462,"type":44},"2026-02-13",{"date":464,"type":44},"2024-09-10",{"date":466,"type":22},"2026-12-31",{"name":468,"class":51},"Indiana University",{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":475,"eligibilityCriteria":476,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":23,"phases":479,"briefSummary":480,"conditions":481,"keywords":482,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":205},"100579737","patient-reported-experiences-with-sparing-external-oblique-fascia-vs-standard-inguinal-orchiectomy-100579737","NCT06828185","Patient Reported Experiences With Sparing External Oblique Fascia Vs Standard Inguinal Orchiectomy","Patient Reported Experiences With Sparing ExteRnal Oblique Fascia Vs Standard Inguinal OrchiEctomy","PRESERVE","Inclusion Criteria:\n\n* Participants undergoing radical orchiectomy for suspected testicular malignancy\n* Testicular malignancy can be germ cell tumor or non germ cell tumors, including paratesticular tumors as long as a radical orchiectomy is planned\n* Participants over 18 years of age who can provide informed consent\n* Participants not currently using opiates for another reason\n* Regional and metastatic patients are allowed, as long as participant does not require opiates for pain related to metastatic disease\n* No contraindication for participant to receive standardized medication pathway in the peri-operative period.\n\nExclusion Criteria:\n\n* Clinical T4 disease\n* History of illicit substance abuse (including prior opioid abuse) except for marijuana\n* Participants who underwent chemotherapy or radiotherapy prior to orchiectomy\n* Opioid use within 1 month of study enrollment\n* Participants with large testis masses requiring skin incision larger than 8 cm in size.\n* Participants with large testis masses requiring orchiectomy through an incision other than the standard transverse inguinal incision (i.e. hockey stick incision, vertical incision)",{"count":478,"type":22},80,[25],"The purpose of this study is to evaluate the difference in patient-reported postoperative outcomes between two standard-of-care surgical techniques for radical orchiectomy (inguinal orchiectomy versus external oblique fascia sparing orchiectomy) for treatment of patients with suspected testicular malignancy. The main questions it aims to answer are:\n\n1. Does sparing the external oblique fascia during orchiectomy reduce pain after surgery?\n2. Is there a difference in narcotic consumption after surgery?\n3. Is there a difference in neuropathic pain after surgery?\n4. Is there a difference in complications after surgery?",[28],[483,484,485,486],"orchiectomy","postoperative pain","testis cancer","germ cell tumors","2026-02-02",{"date":489,"type":44},"2026-02-04",{"date":491,"type":22},"2026-05",{"date":493,"type":22},"2029-09",{"name":495,"class":51},"Loma Linda University",{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":500,"acronym":501,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":61,"minAge":19,"maxAge":503,"enrollmentInfo":504,"targetDuration":4,"studyType":23,"phases":506,"briefSummary":507,"conditions":508,"keywords":510,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":518,"locationsCount":520},"100582719","phase-2-a-single-arm-phase-ii-clinical-trial-of-aspirin-to-prevent-venous-thromboembolism-in-patients-with-advanced-germ-cell-tumors-receiving-chemotherapy-100582719","NCT06866964","A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy","ASPIRE","Inclusion Criteria:\n\n1. Written informed consent and HIPAA authorization for release of personal health information\n2. Age ≥ 18 years and ≤ 70 years at the time of consent\n3. Histological confirmation of stage IS or IIA or higher testicular or germ cell cancer. Primary mediastinal and retroperitoneal GCT are allowed. Seminoma and non-seminoma histologies are allowed.\n4. Performance Status (PS) of ECOG 0-2 at the time of enrollment\n5. At least one of the following \"high risk\" of VTE features:\n\n   a. Stage IIC or III or higher per AJCC 8th edition criteria i. Stage IIC - any pT\u002FTX, N3, M0, S0-1 ii. Stage III - any pT\u002FTX, any N, M1, SX iii. Stage IIIA - any pT\u002FTX, any N, M1a, S0-1 iv. Stage IIIB - any pT\u002FTX, N1-3, M0, S2 or any pT\u002FTX, any N, M1a, S2 v. Stage IIIC - any pT\u002FTX, N1-3, M0, S3 or any pT\u002FTX, any N, M1a, S3 or any pT\u002FTX, any N, M1b, any S Serum marker (S category) S criteria SX Marker studies not available or not performed S0 Marker study levels within normal limits S1 LDH \\\u003C 1.5 x normal and hCG \\\u003C 5000 IU\u002FL and AFP \\\u003C1000 ng\u002FmL S2 LDH 1.5 to 10 x normal or hCG 5000 to 50,000 IU\u002FL or AFP 1000 to 10,000 ng\u002FmL S3 LDH \\>10 x normal or hCG \\>50,000 IU\u002FL or AFP \\>10,000 ng\u002FmL\n\n   b. Intermediate or poor risk by IGCCCG criteria i. Intermediate risk - testis\u002Fretroperitoneal primary and no non pulmonary visceral metastases plus at least one of the following markers: AFP \\> 1,000 ng\u002FmL to ≤ 10,000 ng\u002FmL, beta-hCG \\> 5,000 IU\u002FL and ≤ 50,000 IU\u002FL, LDH \\>1.5 x normal and ≤ 10 x normal ii. Poor risk - mediastinal primary or non-pulmonary visceral metastases plus at least one of the following markers: AFP \\> 10,000 ng\u002FmL, beta- hCG \\> 50,000 IU\u002FL, LDH \\> 10 x normal c. Khorana score of 2 or higher i. +1 point for testicular\u002Fgerm cell cancer (All patients will receive +1 for their testicular\u002Fgerm cell cancer diagnosis. Thus, a patient with any other Khorana characteristic \\[ii-v\\] will meet this inclusion criteria.) ii. +1 point for platelet ≥350 x 10\\^9\u002FL iii. +1 point for hemoglobin \\\u003C10 g\u002FdL iv. +1 point for leukocyte count \\>11 x 10\\^9\u002FL v. +1 point for BMI \\>35 kg\u002Fm\\^2\n6. Planning or recently started 3-4 cycles of standard of care front-line cisplatin-based chemotherapy (bleomycin, etoposide, and platinum \\[BEP\\], etoposide and cisplatin \\[EP\\], or etoposide, ifosfamide, and cisplatin \\[VIP\\]). Note: ASA should be initiated no later than 2 weeks after initiation of standard front-line chemotherapy.\n7. As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study\n8. Ability to swallow oral medications\n\nExclusion Criteria:\n\n1. Receiving chemotherapy in adjuvant setting\n2. Prior VTE\u002FPE\n3. Currently taking anticoagulation or antiplatelet therapy. Non-steroidal anti-inflammatory drug (NSAID) use for pain is allowed\n4. Prior indication for anticoagulation or anticoagulation contraindicated (e.g., active bleed or risk of bleeding, such as history of gastrointestinal ulcers)\n5. Allergy to ASA","70 Years",{"count":505,"type":22},35,[216],"The purpose of this study is to the 6-month Venous Thromboembolism (VTE)-free rate in participants with advanced germ cell cancer at high risk of VTE who are receiving standard of care cisplatin-based chemotherapy and low-dose acetylsalicylic acid (ASA) and compare to relevant historical controls",[509,28],"Germ Cell Tumor",[511,512],"cancer","Venous thromboembolism","2026-01-30",{"date":487,"type":44},{"date":516,"type":44},"2025-08-28",{"date":48,"type":22},{"name":519,"class":51},"Wake Forest University Health Sciences",3,{"id":522,"slug":523,"hasResults":12,"nctId":524,"briefTitle":525,"officialTitle":525,"acronym":526,"eligibilityCriteria":527,"healthyVolunteers":12,"sex":61,"minAge":19,"maxAge":326,"enrollmentInfo":528,"targetDuration":4,"studyType":23,"phases":530,"briefSummary":531,"conditions":532,"keywords":534,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":537,"lastUpdatePostDateStruct":538,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":543,"locationsCount":205},"100544659","symptom-management-and-transitioning-to-engagement-with-post-treatment-care-for-adolescent-and-young-adult-cancer-survivors-100544659","NCT06371768","Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors","AYA STEPS","Inclusion Criteria:\n\n* Diagnosed with one of the following cancers: 1) stage I-III breast cancer; 2) stage I-III colorectal cancer; 3) stage I-III sarcoma; 4) stage I-III Hodgkin or non-Hodgkin lymphoma; or 5) stage I-II testicular cancer\n* treated with curative intent and off therapy (with the exception of endocrine\u002Fhormonal therapy or oral targeted therapies used to prevent disease recurrence or progression) for the last three months\n* 1 to 5 years post-diagnosis\n* Able to speak and read English\n* Able to give informed consent\n\nExclusion Criteria:\n\n* moderate or severe cognitive impairment\n* severe untreated mental illness (e.g., schizophrenia, substance use disorder) that would interfere with providing meaningful consent\u002Fstudy participation",{"count":529,"type":22},260,[25],"The purpose of this study is to determine the effectiveness of a digital health program called AYA STEPS, which is designed to help adolescent and young adult (AYA) cancer survivors manage symptoms and engage in recommended follow-up care.",[224,149,533,87,370,28],"Colorectal Cancer",[224,535,536],"Young Adult","Behavioral Symptom Management","2026-01-26",{"date":539,"type":44},"2026-01-28",{"date":541,"type":44},"2025-07-14",{"date":354,"type":22},{"name":544,"class":51},"Duke University",{"id":546,"slug":547,"hasResults":12,"nctId":548,"briefTitle":549,"officialTitle":550,"acronym":4,"eligibilityCriteria":551,"healthyVolunteers":12,"sex":61,"minAge":19,"maxAge":4,"enrollmentInfo":552,"targetDuration":4,"studyType":23,"phases":553,"briefSummary":554,"conditions":555,"keywords":561,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":570,"locationsCount":205},"100601156","phase-1-a-study-of-gv20-0251-in-advanced-or-refractory-solid-tumors-100601156","NCT07106827","A Study of GV20-0251 in Advanced or Refractory Solid Tumors","Single Arm Clinical Study Protocol of GV20-0251 in the Treatment of Advanced\u002FRefractory Solid Tumors","Inclusion Criteria:\n\n* Before conducting any study-specific procedures, voluntarily sign an informed consent form.\n* Be able and willing to participate throughout the entire study period and comply with study procedures.\n* participants ≥18 years of age\n* Previously treated, histologically-confirmed advanced solid malignancy with progressive disease requiring therapy (Refractory or intolerant to standard therapies, must have received the standard of care therapy)\n* ECOG performance status of 0 or 1 before C1D1\n* Disease-free of active second\u002Fsecondary or prior malignancies for ≥ 2 years Laboratory test results within the required parameters\n* Women of childbearing potential (WOCBP) and men must agree to use adequate contraception\n\nExclusion Criteria:\n\n* Participants with acute leukemia or CLL\n* Participant with heart disease, myocardial infarction within the past 6 months, or unstable arrhythmia\n* Fridericia-corrected QT interval (QTcF) \\> 470 msec, or the presence of congenital long QT syndrome, or a history of clinically significant electrocardiogram (ECG) abnormalities (including pericarditis) that, in the investigator's judgment, may affect the subject's safety.\n* Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy within 7 days of Cycle 1 Day 1 (C1D1)\n* Participant has active autoimmune disease or other medical conditions requiring chronic systemic steroid or immunosuppressive therapy\n* Known human immunodeficiency virus (HIV) infection, known hepatitis B virus (HBV), or hepatitis C virus (HCV) infection, unless meeting the specific conditions.\n* History of major organ transplant and\u002For a bone marrow transplant\n* Symptomatic central nervous system (CNS) malignancy or metastasis\n* Serious nonmalignant disease\n* Pregnant or nursing women\n* Major surgery within 28 days prior to the first dose of study medication\n* Prior anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) before the first dose of GV20-0251 on Cycle 1 Day 1 (C1D1), with the exceptions.\n* History of severe allergic reactions to biologic therapy, which in the investigator's judgment may increase the subject's risk.\n* Radiation therapy for symptomatic lesions within 14 days prior to C1D1 dosing.\n* Active substance abuse\n* Any history of an immune-related ≥ Grade 3 AE attributed to prior cancer immunotherapy",{"count":52,"type":22},[215],"This is a single-arm, single-center study for multiple tumor indications to evaluate the safety of GV20-0251. The trial uses a 3 + 3 design and enrolls 3-6 patients in the 10 mg\u002Fkg and 20 mg\u002Fkg dose groups, respectively. The cancer types include solid tumors.",[556,557,78,558,559,560,72,28],"HCC - Hepatocellular Carcinoma","Cholangiocarcinoma","NSCLC (Non-small Cell Lung Cancer)","Pancreatic Ductal Adenocarcinoma","HNSCC",[562],"GV20-0251","2025-11-18",{"date":565,"type":44},"2025-11-24",{"date":567,"type":44},"2025-09-04",{"date":569,"type":22},"2028-06-11",{"name":571,"class":51},"West China Hospital",{"id":573,"slug":574,"hasResults":12,"nctId":575,"briefTitle":576,"officialTitle":576,"acronym":4,"eligibilityCriteria":577,"healthyVolunteers":12,"sex":61,"minAge":4,"maxAge":4,"enrollmentInfo":578,"targetDuration":580,"studyType":65,"phases":4,"briefSummary":581,"conditions":582,"keywords":614,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":632,"completionDateStruct":634,"leadSponsor":636,"locationsCount":638},"100320510","synergy-ai-artificial-intelligence-based-precision-oncology-clinical-trial-matching-and-registry-100320510","NCT03452774","SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","Inclusion Criteria:\n\n* Pts with solid and hematological malignancies;\n* Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2, HER2\u002FNeu, Tumor mutational burden\u002Fload (TMB), ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, APC, AR, ATM, ATRX, AURKA, AURKB, BAP1, BCL2, BCL6, BRAF, BRCA1, BRCA2, BTK, CCND1, CCND2, CCND3, CDK4, CDK6, CDKN1A\u002FB, CEBPA, CHEK1, CHEK2, CSF1R, CTNNB1, DAXX, DDR1\u002F2, DNMT3A, EGFR, ERBB2, ERBB3, ERBB4, ERCC4, ER, ESR1, FANCA, FAS, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GATA3, GATA6, GNAS, HDAC1, HGF, HRAS, IDH1, IDH2, IGF1R, JAK1, JAK2, JAK3, KDR (VEGFR2), KIT, KRAS, MAP2K2 (MEK2), MAP3K1, MCL1, MDM2, MDM4, MEN1, MET, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCL (MYCL1), NF1, NF2, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PARP1, PARP2, PARP3, PBRM1, PDCD1 (PD1), PDCD1LG2 (PD-L2), PDGFRA, PDGFRB, PIK3C, PMS2, POLD1, POLE, PRDM1, PTCH1, PTEN, RAF1, RB1, RET, RICTOR, ROS1, RPTOR, SDHA\u002FB\u002FC, SMAD, SMARC, SMO, STK11, TGFBR2, TP53, TSC1, TSC2, VEGFA, VHL, WT1, ZNF217, ZNF703, CEACAM, NRG1, among others.\n\nThese biomarkers should be determined by local laboratory, external vendor, or next generation sequencing platform\n\n* Decision to consider clinical trial pre-screening enrollment (CTE) by primary provider and\u002For patient\n\nExclusion Criteria:\n\n* ECOG PS \\> 2;\n* Abnormal organ function;\n* Hospice enrollment",{"count":579,"type":22},50000,"36 Months","International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.",[583,224,584,585,586,587,588,589,590,591,592,593,594,595,596,597,598,599,153,600,601,602,603,150,279,557,604,146,78,605,70,82,72,28,149,606,607,608,609,610,611,612,613],"Cancer, Metastatic","Cancer of Pancreas","Cancer of Liver","Cancer of Stomach","Cancer Liver","Cancer of Rectum","Cancer of Kidney","Cancer of Esophagus","Cancer of Cervix","Cancer of Colon","Cancer of Larynx","Cancer, Lung","Cancer, Breast","Cancer, Advanced","Cancer Prostate","Cancer of Neck","Cancer of Skin","Carcinoma","Mismatch Repair Deficiency","BRCA Gene Rearrangement","Non Hodgkin Lymphoma","Glioblastoma","Urothelial Carcinoma","COVID","Myelofibrosis","Myeloproliferative Neoplasm","Myeloproliferative Disorders","Follicular Lymphoma","Mantle Cell Lymphoma","Marginal Zone Lymphoma","Myelodysplastic Syndromes",[615,616,617,618,619,620,621,622,623,624,625,511,626,627,628],"artificial intelligence","virtual tumor board","clinical trial","clinical trial matching","electronic medical record","machine learning","cost of care","targeted therapy","immunotherapy","precision medicine","precision oncology","value based care","real world data","data analytics","2025-10-25",{"date":631,"type":44},"2025-10-28",{"date":633,"type":44},"2018-01-01",{"date":635,"type":22},"2040-06",{"name":637,"class":104},"Massive Bio, Inc.",68,{"id":640,"slug":641,"hasResults":12,"nctId":642,"briefTitle":643,"officialTitle":644,"acronym":645,"eligibilityCriteria":646,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":647,"targetDuration":4,"studyType":23,"phases":648,"briefSummary":649,"conditions":650,"keywords":651,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":653,"lastUpdatePostDateStruct":654,"startDateStruct":656,"completionDateStruct":658,"leadSponsor":660,"locationsCount":205},"100587751","phase-2-a-clinical-trial-of-primary-retroperitoneal-lymph-node-dissection-in-patients-with-testicular-seminoma-with-limited-retroperitoneal-metastases-100587751","NCT06932458","A Clinical Trial of Primary Retroperitoneal Lymph Node Dissection in Patients With Testicular Seminoma With Limited Retroperitoneal Metastases","A Phase II Single-arm Clinical Trial of Primary Retroperitoneal Lymph Node Dissection in Patients With Testicular Seminoma With Limited Retroperitoneal Metastases","RPLND-Seminoma","Inclusion Criteria:\n\n1. Adult patients (\\>18 years) with pure seminoma on radical orchiectomy specimen.\n2. Initial CS I presentation with subsequent retroperitoneal relapse on surveillance, or de novo CS II at presentation.\n3. Axial imaging of lymphadenopathy within 8 weeks of the date of RPLND\n\n   1. No more than 2 enlarged retroperitoneal lymph nodes, each no more than 3cm in the primary landing zones.\n   2. Suitable for proposed bilateral RPLND template\n4. Serum tumour markers (alpha-fetoprotein (AFP), human chorionic gonadotropin (HCG), and lactate dehydrogenase (LDH)) must all be within normal limits within 2 weeks of planned RPLND\n\nExclusion Criteria:\n\n1. Any condition deemed by the treating surgeon to pose an unacceptable risk for retroperitoneal lymph node dissection\n2. Any non-seminoma component on the orchiectomy specimen.\n3. AFP \\>20 at any time point, pre- or post-orchiectomy.",{"count":270,"type":22},[216],"Testicular cancer represents 1% of adult neoplasms and is the most common solid malignancy in young men. At diagnosis, approximately 90% of cases are germ cell tumours (GCT), categorised as either seminoma (55-60%) or non-seminoma types (40-45%).\n\nFor many years, the management of patients with CS IIA\u002FB seminoma and retroperitoneal lymph node involvement ≤ 3 cm are eligible for treatment with either radiotherapy or chemotherapy Despite high cure rates for CS II seminoma (approximately 90%) with chemotherapy or radiotherapy, concerns persist regarding short and long-term treatment-related toxicities (such as increased risks of cardiovascular disease and secondary malignancies As such, an alternative strategy which has been explored in this study is the role of RPLND for the management of these patients",[28],[401,652],"Retroperitoneal lymph node dissection","2025-07-16",{"date":655,"type":44},"2025-07-20",{"date":657,"type":22},"2025-07-17",{"date":659,"type":22},"2030-06-01",{"name":661,"class":51},"Western University, Canada",{"id":663,"slug":664,"hasResults":12,"nctId":665,"briefTitle":666,"officialTitle":667,"acronym":668,"eligibilityCriteria":669,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":670,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":672,"conditions":673,"keywords":674,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":676,"lastUpdatePostDateStruct":677,"startDateStruct":678,"completionDateStruct":680,"leadSponsor":682,"locationsCount":205},"100589424","voiding-and-erectile-function-after-retroperitoneal-lymph-node-dissection-for-testicular-cancer-100589424","NCT06954233","Voiding and Erectile Function After Retroperitoneal Lymph Node Dissection for Testicular Cancer","Voiding, Erectile and Ejaculatory Function After Retroperitoneal Lymph Node Dissection for Testicular Cancer","VEEF-RPLND-TC","Inclusion Criteria:\n\n* Adult male with testicular cancer undergoing retroperitoneal lymph node dissection (RPLND)\n\nExclusion Criteria:\n\n* History of RPLND\n* Lack of consent",{"count":671,"type":22},20,"This study aims to evaluate how retroperitoneal lymph node dissection (RPLND), a surgical treatment for testicular cancer, may affect urinary and sexual functions in men. RPLND involves the removal of lymph nodes from the abdominal area and is sometimes necessary in patients who are not eligible for chemotherapy or who have residual disease after chemotherapy. While this surgery is known to carry a risk of affecting ejaculation, its potential impact on other areas such as urination or erection is not well understood.\n\nThe study will prospectively follow adult men undergoing RPLND. It will assess changes in lower urinary tract symptoms, urine flow, ejaculation, erection, and overall quality of life before surgery and during follow-up visits up to 6 months after the operation. Patients will complete standardized questionnaires and undergo simple, non-invasive tests such as urine flow measurement.\n\nBy identifying how RPLND may influence urinary and sexual health, this study seeks to improve understanding of the full range of effects of this treatment. The findings may help clinicians better inform patients before surgery and support improved post-operative care.",[28],[28,675],"Retroperitoneal Lymph Node Dissection","2025-07-13",{"date":653,"type":44},{"date":679,"type":44},"2025-05-14",{"date":681,"type":22},"2027-12",{"name":683,"class":51},"Jagiellonian University",{"id":685,"slug":686,"hasResults":12,"nctId":687,"briefTitle":688,"officialTitle":689,"acronym":4,"eligibilityCriteria":690,"healthyVolunteers":12,"sex":61,"minAge":19,"maxAge":326,"enrollmentInfo":691,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":693,"conditions":694,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":698,"lastUpdatePostDateStruct":699,"startDateStruct":701,"completionDateStruct":703,"leadSponsor":705,"locationsCount":205},"100444075","early-ageing-during-therapy-in-aya-cancer-patients-100444075","NCT05062707","Early Ageing During Therapy in AYA Cancer Patients","Longitudinal Assessment of Therapy-related Early Ageing in Adolescent and Young Adult (AYA) Cancer Patients","Inclusion Criteria:\n\n* Aged 18-39 years at cancer diagnosis\n* Having a histologically and\u002For cytologically confirmed cancer diagnosis, including leukemia, (non-)Hodgkin lymphoma, testicular cancer, osteosarcoma, Ewing sarcoma, breast cancer, and cervical cancer.\n* Scheduled to start systemic therapy with curative intent. Allowed treatments (concurrent or sequential) are: surgery, radiotherapy, chemotherapy, antibodies.\n\nExclusion Criteria:\n\n* patients who are not able to understand the patient information letter and informed consent form\n* patients who will be treated with immune checkpoint inhibitors or targeted therapy with inhibitors of angiogenesis\n* patients who have been treated with systemic therapy or radiotherapy for a previous malignancy (exceptions: in situ carcinoma of the cervix or uterus and adequately treated basal and squamous cell carcinoma of the skin).",{"count":692,"type":22},120,"Longitudinal cohort study; measurements before start of systemic therapy and one year later.",[224,150,695,28,696,697,149,71],"Hodgkin Lymphoma","Osteosarcoma","Ewing Sarcoma","2025-05-12",{"date":700,"type":44},"2025-05-13",{"date":702,"type":44},"2022-02-10",{"date":704,"type":22},"2025-07",{"name":706,"class":51},"University Medical Center Groningen",{"id":708,"slug":709,"hasResults":12,"nctId":710,"briefTitle":711,"officialTitle":711,"acronym":4,"eligibilityCriteria":712,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":326,"enrollmentInfo":713,"targetDuration":4,"studyType":23,"phases":715,"briefSummary":716,"conditions":717,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":718,"lastUpdatePostDateStruct":719,"startDateStruct":721,"completionDateStruct":723,"leadSponsor":725,"locationsCount":205},"100503548","a-biobehavioral-intervention-to-reduce-adverse-outcomes-in-young-adult-testicular-cancer-survivors-100503548","NCT05836688","A Biobehavioral Intervention to Reduce Adverse Outcomes in Young Adult Testicular Cancer Survivors","Inclusion Criteria:\n\n* Age 18 to 39 years at time of consent\n* A confirmed diagnosis of testis cancer (any stage)\n* Completion of chemotherapy for testis cancer within 4 years prior to consent\n* A score of \\>4 on the Distress Thermometer\n* English fluency, as per medical record documenting preferred language or in the judgment of the investigator\n* Spanish fluency, as per medical record documenting preferred language or in the judgment of the investigator\n* Able to perform informed consent\n\nExclusion Criteria:\n\n* Lifetime history of psychiatric of cognitive disturbance as per self-report or medical record\n* In the judgment of the consenting professional, is unable to provide informed consent and complete study sessions and assessment\n* As per self-report, has medical conditions that affect the immune system and would confound immune evaluation (e.g., autoimmune disorder, inflammatory disease; uncontrolled thyroid disease; active infection; myocardial infarction or stroke in the last 6 months; Type I diabetes; acute hepatitis; recent vaccination for viral disease)\n* Regular smoker (daily use)",{"count":714,"type":22},250,[25],"This study is a randomized controlled biobehavioral efficacy trial designed to investigate the feasibility and acceptability of a novel intervention, Goal-focused Emotion-Regulation Therapy (GET) aimed at improving distress symptoms, emotion regulation, goal navigation skills, and stress-sensitive biomarkers in young adult testicular cancer patients.\n\nParticipants will be randomized to receive six sessions of GET or Individual Supportive Listening (ISL) delivered over eight weeks. In addition to indicators of intervention feasibility, the investigators will measure primary (depressive and anxiety symptoms) and secondary (emotion regulation and goal navigation skills, career confusion) psychological outcomes prior to (T0), immediately after (T1), twelve weeks after intervention (T2) and 24 weeks after the intervention (T3). Additionally, identified biomarkers will be measured at baseline and at T1, T2, and T3.",[28],"2025-04-29",{"date":720,"type":44},"2025-05-01",{"date":722,"type":44},"2023-11-01",{"date":724,"type":22},"2028-07",{"name":726,"class":51},"University of California, Irvine",{"id":728,"slug":729,"hasResults":12,"nctId":730,"briefTitle":731,"officialTitle":731,"acronym":4,"eligibilityCriteria":732,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":733,"targetDuration":735,"studyType":65,"phases":4,"briefSummary":736,"conditions":737,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":738,"lastUpdatePostDateStruct":739,"startDateStruct":741,"completionDateStruct":743,"leadSponsor":745,"locationsCount":291},"100578101","twenty-years-experience-in-retroperitoneal-lymph-node-dissection-for-testicular-cancer-in-a-tertiary-referral-center-100578101","NCT06806917","Twenty Years' Experience in Retroperitoneal Lymph Node Dissection for Testicular Cancer in a Tertiary Referral Center","Inclusion Criteria:\n\n* Aged ≥ 18 years\n* RPLND of residual mass after chemotherapy in patient with testicular neoplasm seminomatous or nonseminomatous performed by open, laparoscopic, or robotic technique\n* Primary RPLND for seminomatous or nonseminomatous testicular neoplasm of stage I or IIA-IIB with negative markers performed with open, laparoscopic or robotic technique\n* RPLND performed by open, laparoscopic, or robotic technique for the treatment of tumors seminomatous or nonseminomatous chemiorefractory testicular tumors progressing after I and II line of chemotherapy\n* Acquisition of informed consent\n\nExclusion criteria:\n\n* Patient with comorbidities with contraindication to surgery\n* Hemorrhagic diathesis\n\nRETROSPECTIVE PHASE. Patients with the same inclusion and exclusion criteria as in the prospective phase and already undergoing RPLND surgery with open, laparoscopic, or robotic technique from January 2000 to December 2020 in the͛framework of the normal course of care with a minimum follow-up of 12 months. (estimated to include approximately 120 patients).",{"count":734,"type":22},65,"5 Years","The aim of this study is to evaluate the oncologic and functional outcomes of RPLND as primary treatment (stage I and IIA-IIB with negative markers) or of residual masses after chemotherapy (PC-RPLND) in the treatment of patients with seminomatous and non-seminomatous.\n\nIn order to evaluate the role and the͛clinical impact of different surgical techniques of RPLND will be included patients treated with open, laparoscopic, and robot-assisted techniques",[28],"2025-01-28",{"date":740,"type":44},"2025-02-04",{"date":742,"type":44},"2021-12-01",{"date":744,"type":22},"2031-10-31",{"name":746,"class":51},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":748,"slug":749,"hasResults":12,"nctId":750,"briefTitle":751,"officialTitle":751,"acronym":4,"eligibilityCriteria":752,"healthyVolunteers":12,"sex":61,"minAge":19,"maxAge":4,"enrollmentInfo":753,"targetDuration":4,"studyType":23,"phases":754,"briefSummary":755,"conditions":756,"keywords":760,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":765,"lastUpdatePostDateStruct":766,"startDateStruct":768,"completionDateStruct":770,"leadSponsor":772,"locationsCount":205},"100568676","phase-2-multi-cohort-single-arm-phase-ii-study-of-albumin-paclitaxel-ifosfamide-and-cisplatin-in-the-treatment-of-rare-advanced-tumors-100568676","NCT06684327","Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of Rare Advanced Tumors","Inclusion Criteria:\n\n* Individuals able to understand and give written informed consent.\n* Histologically or cytologically confirmed cancer of one of the following types:\n\nPAGET's disease of scrotum with infiltrating sweat gland carcinoma Rhabdomyosarcoma Testicular cancer Penile cancer Urachal cancer\n\n* Stage IV disease\n* Adequate performance status (ECOG 0-2)\n* Expected survival ≥ 3 months.\n* Measurable disease by CT or MRI, Or lesions with skin infiltration.\n* Adequate hematology without ongoing transfusional support (hemoglobin \\> 9 g\u002FdL, absolute neutrophil count (ANC) \\> 1,500 per mm\\^3, platelets \\> 100,000 per mm\\^3).\n* Adequate renal and hepatic function (creatinine ≤ 2.0 x institutional upper limit of normal (IULN), bilirubin ≤ 1.5 IULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x IULN or 5 x IULN if know liver metastases).\n* Adequate coagulation function: International Normalized Ratio (INR) ≤1.5 \u002FPT≤1.5×ULN, aPTT≤1.5×ULN.\n* Willing to use a medically approved contraceptive method from the enrollment to at least 120 days after the end of the study, and sperm donation to another person or cryopreservation for fertilization and reproduction is not permitted during this period.\n* Ability to comply with research visit schedules and other protocol requirements.\n\nExclusion Criteria:\n\n* 1\\. Active or uncontrolled severe infections (≥CTCAE Level 2) requiring systemic antibacterial, antifungal, or antiviral therapy, including tuberculosis infections.\n* 2\\. Active hepatitis (transaminases not within inclusion criteria; HBV reference: HBV DNA ≥2000 IU\u002Fml or ≥10\\^4 copies\u002Fml; HCV reference: HCV RNA ≥2000 IU\u002Fml or ≥10\\^4 copies\u002Fml; after nucleoside antiviral treatment below the above standards, may be eligible; chronic HBV carrier with HBV DNA \\\u003C10\\^4 IU\u002Fml, must receive antiviral treatment during the study period to be eligible).\n* 3\\. Renal failure requiring hemodialysis or peritoneal dialysis.\n* 4\\. History of immunodeficiency, including HIV positive or having other acquired\u002Fcongenital immunodeficiency diseases, or organ transplant history.\n* 5\\. Severe nausea, headache, insomnia, fatigue, somnolence, dry mouth, dizziness, and constipation.\n* 6\\. History of active tuberculosis.\n* 7\\. Uncontrolled ascites, pleural effusion, or pericardial effusion requiring repeated drainage.\n* 8\\. Patients who have undergone major organ transplantation.\n* 9\\. Individuals who have undergone major surgical procedures, open biopsies, or obvious traumatic injuries within 28 days prior to the start of the study; or have unhealed wounds or fractures for a long time;\n* 10\\. Individuals who have participated or are currently participating in another clinical study within the past 4 weeks prior to the start of the study;\n* 11\\. Individuals with a history of severe allergies;\n* 12\\. Individuals at risk of bleeding, or with impaired coagulation function, or who are currently receiving thrombolytic therapy;\n* 13\\. Individuals with a history of substance abuse with no ability to abstain or with a mental disorder.\n* 14\\. According to the investigator's judgment, subjects with serious adverse effects on their safety or completion of the study, or those with accompanying diseases that seriously endanger the safety of the subjects or affect the completion of the study, or those with other reasons deemed unsuitable for enrollment by the investigator. Subjects with a history of a clearly defined neurological or psychiatric disorder, such as dementia, epilepsy, or a history of epilepsy prone.",{"count":64,"type":22},[216],"The goal of this clinical trial is to learn if albumin-paclitaxel, ifosfamide and cisplatin (Nab-TIP) works to treat advanced rare tumors including PAGET's disease of scrotum with infiltrating sweat gland carcinoma （cohort 1）, rhabdomyosarcoma (cohort 2), testicular cancer (cohort 3), penile cancer (cohort 4), and urachus cancer (cohort 5) . It will also learn about the safety of Nab-TIP. The main questions it aims to answer are:\n\nDoes Nab-TIP improve the objective response rate and prolong the survival of participants? What medical problems do participants have when receiving the regimen of Nab-TIP?\n\nParticipants will:\n\nReceive albumin-paclitaxel 260mg\u002Fm2 d1, isocyclophosphamide 1500mg\u002Fm2 d2-5, and cisplatin 25mg\u002Fm2 d2-5 every 21 days until disease progression, intolerable toxicity, or full 6 cycles of treatment, whichever occurs first.\n\nBe performed imaging evaluation according to RECIST 1.1 every 6 weeks for 1 year of treatment and every 12 weeks after 1 year Be recorded any adverse events in the whole study period including type, incidence, grade, severity, duration, and association with the study drug according to NCI-CTCAE V5.0 criteria",[757,758,28,135,759],"Paget Disease, Extramammary","Rhabdomyosarcoma","Urachal Cancer",[761,762,763,764],"rare tumor","albumin-paclitaxel","ifosfamide","cisplatin","2024-12-18",{"date":767,"type":44},"2024-12-20",{"date":769,"type":44},"2024-11-30",{"date":771,"type":22},"2027-12-30",{"name":773,"class":51},"Fudan University",{"id":775,"slug":776,"hasResults":12,"nctId":777,"briefTitle":778,"officialTitle":778,"acronym":4,"eligibilityCriteria":779,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":780,"enrollmentInfo":781,"targetDuration":4,"studyType":23,"phases":783,"briefSummary":784,"conditions":785,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":786,"lastUpdatePostDateStruct":787,"startDateStruct":789,"completionDateStruct":791,"leadSponsor":793,"locationsCount":205},"100371188","senescence-and-the-early-ageing-phenotype-after-chemotherapy-for-testicular-cancer-the-sea-cat-study-100371188","NCT04113122","Senescence and the Early Ageing Phenotype After Chemotherapy for Testicular Cancer: the SEA-CAT Study","Inclusion Criteria:\n\nIn order to be eligible to participate in the cross-sectional part of this study, a subject must meet all of the following criteria:\n\n* Diagnosed with metastatic testicular cancer in 1999-2012 (stage II or higher)\n* Received first-line cisplatin-based chemotherapy\n* Was younger than 50 years of age at start of chemotherapy\n\nIn order to be eligible to participate in the longitudinal part of this study, a subject must meet all of the following criteria:\n\nChemotherapy-group:\n\n* Diagnosis of metastatic testicular cancer (stage II or higher)\n* Is about to start with first-line cisplatin-based chemotherapy\n* Younger than 50 years of age at diagnosis of metastatic testicular cancer\n\nStage I control-group:\n\n* Diagnosis of testicular cancer stage I disease\n* Younger than 50 years of age at diagnosis of testicular cancer\n\nExclusion Criteria:\n\nA potential subject who meets any of the following criteria will be excluded from participation in this study:\n\n\\- Not able to provide informed consent (in example in case of mental or psychiatric disability)","50 Years",{"count":782,"type":22},192,[25],"Cisplatin-combination chemotherapy causes inevitably DNA damage by platinum-DNA adduct formation of both tumor cells but also healthy cells. It therefore stands to reason that testicular cancer treatment causes an increased burden of senescent cells, which causes upregulation of the SASP resulting in a pro-inflammatory phenotype. The investigators hypothesize that this may be an important mechanism behind development of late effects and an early ageing phenotype after treatment for testicular cancer.",[28],"2024-12-09",{"date":788,"type":44},"2024-12-13",{"date":790,"type":44},"2019-02-09",{"date":792,"type":22},"2026-09",{"name":706,"class":51}]